0001493152-18-011091.txt : 20180807 0001493152-18-011091.hdr.sgml : 20180807 20180807165736 ACCESSION NUMBER: 0001493152-18-011091 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 33 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180807 DATE AS OF CHANGE: 20180807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 18998851 BUSINESS ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-Q

 

 

 

(Mark One)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2018

 

or

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from             to

 

Commission file number 001-36457

 

 

 

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   90-0031917

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

     

10025 Investment Drive, Suite 250

Knoxville, Tennessee

  37932
(Address of principal executive offices)   (Zip Code)

 

866-594-5999

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [  ] No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [  ] No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer [  ] Accelerated filer [  ]
       
Non-accelerated filer [  ] (Do not check if a smaller reporting company) Smaller reporting company [X]
       
Emerging growth company [  ]    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ] Yes [X] No

 

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of July 31, 2018, was 383,111,028.

 

 

 

 

 

 

TABLE OF CONTENTS

 

  Page
PART I FINANCIAL INFORMATION  
   
Cautionary Note Regarding Forward-Looking Statements 1
Item 1. Financial Statements (unaudited) 2
Condensed Consolidated Balance Sheets 2
Condensed Consolidated Statements of Operations 3
Condensed Consolidated Statements of Cash Flows 4
Notes to Condensed Consolidated Financial Statements 5
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
Item 3. Quantitative and Qualitative Disclosures About Market Risk 14
Item 4. Controls and Procedures 14
   
PART II OTHER INFORMATION  
   
Item 1. Legal Proceedings 15
Item 1A. Risk Factors 15
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 15
Item 3. Defaults Upon Senior Securities 15
Item 4. Mine Safety Disclosures 15
Item 5. Other Information 15
Item 6. Exhibits 16
   
SIGNATURES 17

 

 

 

 

Cautionary Note Regarding Forward-Looking Statements

 

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations. These statements also express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date, unless otherwise required by law.

 

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2017), and the following:

 

  our potential receipt of sales from investigational drug products PV-10 and PH-10 (if and when approved), transaction fees, licensing and royalty payments, and/or payments in connection with the Company’s liquidation, dissolution or winding up, or any sale, lease, conveyance or other disposition of any intellectual property relating to our investigational drug products, and/or drug substance Rose Bengal (and/or any other halogenated xanthene);
     
  our ability to raise additional capital; and
     
  our ability to close on additional tranches of the financing from a group of the Company’s stockholders (the “PRH Group”) pursuant to the Definitive Financing Commitment Term Sheet we entered into with the PRH Group effective as of March 19, 2017.

 

 1 
 

 

PART I FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

PROVECTUS BIOPHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   June 30,   December 31, 
   2018   2017 
   (Unaudited)     
Assets          
           
Current Assets:          
Cash and cash equivalents  $130,633   $105,504 
Short-term receivables - settlement and other   974,767    452,376 
Prepaid expenses   273,552    400,416 
           
Total Current Assets   1,378,952    958,296 
           
Equipment and furnishings, less accumulated depreciation of $43,492 and $36,445, respectively   79,522    86,569 
Patents, net of accumulated amortization of $10,480,657 and $10,145,098, respectively   1,234,787    1,570,347 
Long-term receivable – reimbursable legal fees, net of reserve for uncollectibility of $455,500   455,500    455,500 
Long-term receivable – settlement, net of discount and reserve for uncollectibility of $1,549,043   377,220    365,685 
           
Total Assets  $3,525,981   $3,436,397 
           
Liabilities and Stockholders’ Deficiency          
           
Current Liabilities:          
Accounts payable - trade  $3,500,467   $3,270,505 
Other accrued expenses   1,363,904    728,735 
           
Total Current Liabilities   4,864,371    3,999,240 
           
Convertible notes payable   6,412,000    4,456,000 
Convertible notes payable - related parties   5,950,000    5,000,000 
           
Total Liabilities   17,226,371    13,455,240 
           
Commitments and contingencies          
Stockholders’ Deficiency:          
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2018 and December 31, 2017; aggregate liquidation preference of $3,500 at June 30, 2018 and December 31, 2017   -    - 
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 383,111,028 and 370,961,451 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively   383,111    370,962 
Additional paid-in capital   209,013,555    208,351,431 
Accumulated deficit   (223,097,056)   (218,741,236)
           
Total Stockholder’s Deficiency   (13,700,390)   (10,018,843)
           
Total Liabilities and Stockholders’ Deficiency  $3,525,981   $3,436,397 

 

See accompanying notes to condensed consolidated financial statements.

 

 2 
 

 

PROVECTUS BIOPHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

  

Three Months Ended

June 30,

  

Six Months Ended

June 30,

 
   2018   2017   2018   2017 
                 
Operating Expenses:                    
Research and development  $987,239   $2,252,890   $2,930,302   $4,006,538 
General and administrative   1,342,210    1,050,004    2,304,928    3,694,529 
                     
Total Operating Loss   (2,329,449)   (3,302,894)   (5,235,230)   (7,701,067)
                     
Gain on settlement of lawsuit   825,000    -    825,000    - 
Research and development tax credit   42,685    -    42,685    - 
Investment income   5,556    8,075    11,725    16,750 
                     
Net Loss   (1,456,208)   (3,294,819)   (4,355,820)   (7,684,317)
                     
Dividend paid-in kind to preferred shareholders   -    (50)   -    (14,057)
                     
Net Loss Applicable to Common Shareholders  $(1,456,208)  $(3,294,869)  $(4,355,820)  $(7,698,374)
                     
Basic and Diluted Loss Per Common Share  $(0.00)  $(0.01)  $(0.01)  $(0.02)
                     
Weighted Average Number of Common Shares Outstanding - Basic and Diluted   381,574,365    370,354,643    379,483,491    367,795,241 

 

See accompanying notes to condensed consolidated financial statements.

 

 3 
 

 

PROVECTUS BIOPHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

   Six Months Ended June 30, 
   2018   2017 
         
Cash Flows From Operating Activities          
Net loss  $(4,355,820)  $(7,684,317)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   7,047    9,422 
Amortization of patents   335,560    335,560 
Issuance of stock for services   80,000    - 
Changes in operating assets and liabilities          
Settlement receivable   (533,926)   183,329 
Other current assets   126,864    115,565 
Accounts payable - trade   229,962    1,354,439 
Other accrued expenses   635,169    98,098 
           
Net Cash Used In Operating Activities   (3,475,145)   (5,587,904)
           
Cash Flows From Financing Activities          
Proceeds from issuance of convertible notes payable   1,956,000    2,550,000 
Proceeds from issuance of convertible notes payable - related party   950,000    3,000,000 
Proceeds from exercise of warrants   594,274    - 
Net Cash Provided By Financing Activities   3,500,274    5,550,000 
           
Net Change In Cash and Cash Equivalents   25,129    (37,904)
           
Cash and Cash Equivalents, Beginning of Period   105,504    1,165,738 
           
Cash and Cash Equivalents, End of Period  $130,633   $1,127,834 
           
Supplemental Disclosures of Cash Flow Information:          
           
Non-cash investing and financing activities:          
Conversion of preferred stock into common stock  $-   $3,987 
Dividend paid-in kind to preferred shareholders  $-   $1,595 
Issuance in-kind of preferred stock dividends  $-   $14,057 

 

See accompanying notes to condensed consolidated financial statements.

 

 4 
 

 

PROVECTUS BIOPHARMACEUTICALS, INC.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

1. Business Organization, Nature of Operations and Basis of Presentation

 

Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on halogenated xanthenes. Intralesional PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal cancers, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses, like psoriasis and atopic dermatitis. To date, the Company has not generated any revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 23, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.

 

2. Liquidity and Going Concern

 

The Company’s cash and cash equivalents were $130,633 at June 30, 2018, compared with $105,504 at December 31, 2017. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10 and PH-10 and to raise additional capital.

 

The Company plans to access capital resources through possible public or private equity offerings, including the 2017 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, but no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2017 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to June 30, 2018, the Company received aggregate Loans of $300,000 in connection with the 2017 Financing. See Note 7 – Subsequent Events.

 

 5 
 

 

The primary business objective of management is to build the Company into a fully integrated global biotechnology company. The Company, however, cannot assure you that it will be successful in co-developing or licensing PV-10, PH-10, or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2018 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2017 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

 

3. Significant Accounting Policies

 

The Company’s significant accounting policies are disclosed in Note 3 – Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

 

Recent Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods beginning after December 15, 2017 for share-based payment awards modified on or after the adoption date. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

 

In March 2018, the FASB issued ASU No. 2018-05, “Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118” (“ASU 2018-05”). ASU 2018-05 adds various “SEC” paragraphs pursuant to the issuance of the December 2017 SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which was effective immediately. The SEC issued SAB 118 to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Cuts and Jobs Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Tax Cuts and Jobs Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has accounted for the tax effects of the Tax Cuts and Jobs Act under the guidance of SAB 118 and does not believe that the adoption of ASU 2018-05 will have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

 6 
 

 

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the Company’s condensed consolidated financial statements.

 

4. Convertible Notes Payable

 

On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the “Term Sheet”) that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $10,000,000 and maximum of $20,000,000 (the “2017 Financing”).

 

The 2017 Financing is in the form of secured convertible loans (the “Loans”) from the PRH Group or other investors in the 2017 Financing (the “Investors”). The Loans are evidenced by secured convertible promissory notes (individually a “PRH Note” and collectively, the “PRH Notes”) from the Company to the PRH Group or the investors.

 

The principal amounts of the PRH Notes and the interest payable under the Loan would automatically convert into shares of the Company’s Series D Preferred Stock at a price per share equal to $0.2862 effective on the 18-month anniversary of the funding of the final tranche of the 2017 Financing subject to certain exceptions if the Company’s Board designates such series of preferred stock in the future.

 

As of June 30, 2018, and through the date of filing, the Series D Preferred Stock had not been designated by the Board and, accordingly, the PRH Notes are not convertible into shares of Series D Preferred Stock. As a result, the Company did not analyze the Loan for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the PRH Notes were not convertible as of their respective dates of issuance or as of June 30, 2018.

 

As of June 30, 2018, the Company had received aggregate Loans of $12,362,000 in connection with the 2017 Financing from both non-related and related parties. For further details on the terms of the PRH Notes, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 23, 2018.

 

Convertible Notes Payable – Related Parties

 

On February 21, 2017, the Company issued a promissory note in favor of Eric A. Wachter, Ph.D., the Company’s Chief Technology Officer (“Wachter”), evidencing an unsecured loan from Wachter to the Company in the original principal amount of up to $2,500,000 (the “Wachter Note”). Interest accrues on the outstanding balance of the Wachter Note at six percent (6%) per annum calculated on a 360-day basis.

 

 7 
 

 

On April 3, 2017, the Company entered into a PRH Note with Cal Enterprises LLC, a Nevada limited liability company, an affiliate of Dominic Rodrigues, a director of the Company, in the principal amount of up to $2,500,000. As of June 30, 2018, the Company had borrowed the entire $2,500,000 under this note.

 

During the six months ended June 30, 2018, the Company amended the above notes to modify the maturity date from 24 months to 18 months in order to be consistent with the other outstanding PRH Notes. The actual maturity dates will be determined after the completion of the 2017 Financing.

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with related parties in the aggregate principal amount of $950,000. As of June 30, 2018, the Company had drawn down the entire $950,000 under these notes.

 

Convertible Notes Payable – Non-Related Parties

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with accredited investors in the aggregate principal amount of $1,956,000. As of June 30, 2018, the Company had drawn down the entire $1,956,000 under these notes. Included in the $1,956,000 is one PRH note totaling $500,000 with terms of principal and interest due twenty-four (24) months from date of signing. This note will mature in June 2020.

 

5. Stockholders’ Deficiency

 

Exercise of Warrants

 

During the six months ended June 30,2018, warrant holders exercised warrants to purchase an aggregate of 11,149,577 shares of commons stock at a price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $594,273 and issued 11,149,577 shares of common stock to the warrant holders.

 

Other Common Stock Issuances

 

During the six months ended June 30, 2018, the Company issued 1,000,000 shares of common stock in payment of services with a grant date fair value of $80,000.

 

As the fair market value of the service was not readily determinable, the service was valued based on the fair market value of the stock at grant date.

 

6. Litigation

 

Culpepper Travel Expenses and Related Collection Efforts

 

On December 27, 2016, the Company’s Board of Directors unanimously voted to terminate Culpepper, effective immediately, from all positions he held with the Company and each of its subsidiaries, including interim Chief Executive Officer and Chief Operating Officer of the Company, “for cause”, in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”) based on the results of the investigation conducted by the Audit Committee of the Board of Directors regarding improper expense reimbursements to Culpepper.

 

The Audit Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Audit Committee in conducting the investigation. The Audit Committee found that Culpepper received $294,255 in expense reimbursements that were unsubstantiated or otherwise improper. The Company seeks to recover from Culpepper the entire $294,255 in expense reimbursements, as well as all attorney’s fees and auditors’/experts’ fees incurred by the Company in connection with the examination of his expense reimbursements. On December 12, 2017, Culpepper agreed to an order by the SEC to pay disgorgement of $140,115, and prejudgment interest of $12,261, for a total of $152,376, to the Company within 30 days. The Company received the payment of $152,376 in January 2018.

 

 8 
 

 

The Company takes the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Derivative Lawsuit Settlement such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,051,083 as of June 30, 2018 and December 31, 2017, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount.

 

Culpepper disputes that he was terminated “for cause” under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating both Culpepper’s claim for severance against Provectus and Provectus’ claims against Culpepper for improper expense reimbursements and amounts Culpepper owes Provectus under the Derivative Lawsuit Settlement (the “Culpepper Arbitration”). The Culpepper Arbitration hearing was held from May 15, 2018 through May 18, 2018.

 

On July 12, 2018, the arbitrator issued an interim award in favor of the Company, the terms of which are confidential pursuant to the terms of the Culpepper Employment Agreement and instructed the parties that a final award is forthcoming.

 

The Bible Harris Smith Lawsuit

 

On November 17, 2016, the Company filed a lawsuit in the Circuit Court for Knox County, Tennessee against Bible Harris Smith PC (“BHS”) for professional negligence, common law negligence and breach of fiduciary duty arising from accounting services provided by BHS to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company further alleges that had BHS provided competent accounting and tax preparation services, it would have discovered Dees’ failure to submit back-up documentation supporting the advanced travel funds at the inception of Dees’ conduct, and prevented the misuse of these and future funds. The Company has made a claim for damages against BHS in an amount in excess of $3 million. The complaint against BHS has been filed and served, an answer has been received, and the parties are in the midst of discovery. BHS filed a Motion for Summary Judgment, which was denied in full by the Court on June 21, 2018.

 

The RSM Lawsuit

 

On June 9, 2017, the Company filed a lawsuit in the Circuit Court of Mecklenburg County, North Carolina against RSM USA LLP (“RSM”) for professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation and breach of fiduciary duty arising from accounting, internal auditing and consulting services provided by RSM to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company similarly alleges that Culpepper received $294,255 in travel expense reimbursements and advances that were unsubstantiated. The Company further alleges that had RSM provided competent accounting, internal audit and consulting services, it would have discovered Dees’ and Culpepper’s conduct at its inception and prevented the misuse of these and future funds. The Company has made a claim for damages against RSM in an amount in excess of $10 million. The Complaint against RSM has been filed and RSM has moved to dismiss the Complaint. The motion to dismiss has been briefed and argued and the parties are awaiting a ruling.

 

 9 
 

 

The BDO Matter

 

On November 16, 2017, the Company filed a demand for arbitration with the American Arbitration Association that alleged professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation, and breach of fiduciary duty by the Company’s former external audit firm, BDO USA LLP (“BDO”), arising from accounting, external auditing, and consulting services provided by BDO related to travel and expense advances and reimbursements received by Dees and former Company executive Culpepper. During the quarter ended June 30, 2018, this matter was resolved pursuant to a settlement between the parties, the terms of which are confidential.

 

Subsequent to June 30, 2018, the proceeds from the settlement were received.

 

7. Subsequent Events

 

Convertible Notes Payable

 

Subsequent to June 30, 2018, the Company entered into a PRH Note with a related party in the principal amount of $200,000 and a PRH Note with a non-related party in the principal amount of $100,000. The Company has received the proceeds of $300,000 relating to these notes.

 

 10 
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited financial statements and our Annual Report on Form 10-K for the year ended December 31, 2017 (“2017 Form 10-K”), which includes additional information about our critical accounting policies and practices and risk factors. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

 

Overview of Core Technologies

 

Provectus is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on halogenated xanthenes, such as Rose Bengal (4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein). Intralesional PV-10, the first small molecule oncolytic immunotherapy, which can induce immunogenic cell death, is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal cancers, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses, like psoriasis and atopic dermatitis. For psoriasis, pathways significantly improved include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons.

 

Our approach to drug development comprises two related, complementary, clinical development program paths based on the features of our investigational drugs and their clinically rational applicability to different patient populations. In solid tumor cancers for adults, for example, we believe PV-10 has important implications as a single agent for earlier states of disease (i.e., locally advanced disease, or Stage III or earlier), while the combination of PV-10 with other classes of therapy or therapeutic agent (e.g., chemotherapy, immunotherapy, radiotherapy, targeted therapy) is more appropriate for more advanced disease states (i.e., widely metastatic disease, or Stage IV).

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2018 and June 30, 2017

 

Research and Development

 

Research and development expenses decreased by $1,265,651, from $2,252,890 for the three months ended June 30, 2017 to $987,239 for the three months ended June 30, 2018, a decrease of approximately 56% year-over-year. The decrease was due primarily to the settlement between the Company and a former contract research organization whereby the Company received a credit for $1,051,116 against its overall amounts due coupled with overall lower contractor cost of $325,854, and conference expense of $25,506, offset by an increase in lab supplies and pharmaceutical preparations of $15,815, payroll of $47,116, travel cost of $61,935, and other costs totaling $11,959.

 

Research and development costs of $987,239 for the three months ended June 30, 2018 included amortization of patents of $167,780, payroll of $133,654, conference expense of $5,000, consulting and contract labor of $484,967, insurance of $75,233, lab supplies and pharmaceutical preparations of $20,390, travel cost of $61,935, rent and utilities of $15,757, depreciation expense of $2,162, and other costs of $20,361.

 

Research and development costs of $2,252,890 for the three months ended June 30, 2017 included patent amortization expense of $167,780, payroll of $86,538, conference expense of $30,506, consulting and contract labor of $1,861,937, insurance of $76,047, lab supplies and pharmaceutical preparations of $4,575, rent and utilities of $18,716, and depreciation expense of $6,791.

 

 11 
 

 

General and Administrative

 

General and administrative expenses increased by $292,206 from $1,050,004 for the three months ended June 30, 2017 to $1,342,210 for the three months ended June 30, 2018, an increase of approximately 28% year-over-year. The increase was due primarily to (i) increased legal expenses of approximately $195,194 related to lawsuits, (ii) an approximate $48,774 increase in directors’ fees, which were accrued, (iii) increased investor relations expense of $79,880, which was paid in shares of common stock, partially offset by (iv) a decrease in information technology charges of $26,120, and (v) other costs savings of $5,522.

 

Comparison of Six Months Ended June 30, 2018 and June 30, 2017

 

Research and Development

 

Research and development expenses decreased by $1,076,236, from $4,006,538 for the six months ended June 30, 2017 to $2,930,302 for the six months ended June 30, 2018, a decrease of approximately 27% year-over-year. The decrease was due primarily to the settlement between the Company and a former contract research organization whereby the Company received a credit for $1,051,116 against its overall amounts due coupled with lower consulting and contract labor cost on clinical trials of $248,980, and other cost reductions of $11,976, partially offset by an increase in travel expense of $103,505, lab supplies and pharmaceutical preparations of $27,223, payroll expense of $93,590, and other cost increases of $11,518.

 

Research and development costs of $2,930,302 for the six months ended June 30, 2018 included patent amortization expense of $335,560, payroll of $273,077, conference expense of $15,000, consulting and contract labor of $1,941,640, insurance of $150,952, lab supplies and pharmaceutical preparations of $41,674, travel cost of $103,505, rent and utilities of $33,616, depreciation expense of $4,324, and other cost of $30,954.

 

Research and development costs of $4,006,538 for the six months ended June 30, 2017 included patent amortization expense of $335,560, payroll of $179,487, conference expense of $34,054, consulting and contract labor of $3,241,736, insurance of $153,888, lab supplies and pharmaceutical preparations of $14,451, rent and utilities of $37,940, and depreciation expense of $9,422.

 

General and Administrative

 

General and administrative expenses decreased by $1,389,601, from $3,694,529 for the six months ended June 30, 2017 to $2,304,928 for the six months ended June 30, 2018, a decrease of approximately 38% year-over-year. The decrease was primarily due to (i) decreased legal expense of $536,681 due to a decline in investigations and litigations, (ii) an approximate $1.1 million decrease in professional fees due to the termination and reduction in scope of certain vendor services contracts, (iii) offset by an increase in director’s fees of $105,024, which were accrued, (iv) a credit of $97,500 applied in 2017 for contributions not contributed, (v) increased rent expense of $14,233, and (vi) other cost increases of $30,323.

 

Investment Income

 

Investment income is immaterial for all periods presented.

 

 12 
 

 

Liquidity and Capital Resources

 

Our cash and cash equivalents were $130,633 at June 30, 2018, compared to $105,504 at December 31, 2017. The condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. We have continuing net losses and negative cash flows from operating activities. In addition, we have an accumulated deficit of $223,097,056 as of June 30, 2018. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. Our financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to obtain additional financing as may be required to fund current operations.

 

Management’s plans include selling our equity securities and obtaining other financing to fund our capital requirement and on-going operations, including the 2017 Financing discussed elsewhere in this filing; however, there can be no assurance we will be successful in these efforts. The financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern. Significant funds will be needed for us to continue and complete our Phase 3 and other clinical trials.

 

Subsequent to June 30, 2018, the Company entered into a PRH Note with a related party in the principal amount of $200,000 and a PRH Note with a non-related party in the principal amount of $100,000. The Company has received the proceeds of $300,000 relating to these notes.

 

Access to Capital

 

Management plans to access capital resources through possible public or private equity offerings, including the 2017 Financing, exchange offers, debt financings, corporate collaborations or other means. If we are unable to raise sufficient capital through the 2017 Financing or otherwise, we will not be able to pay our obligations as they become due.

 

The primary business objective of management is to build the Company into a fully integrated biotechnology company; however, we cannot assure you that management will be successful in implementing its business plan of developing, licensing and/or commercializing our prescription drug candidates. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our current and long-term requirements in 2018 and beyond. We anticipate that these funds will otherwise come from the proceeds of private placement transactions, including the 2017 Financing, the exercise of existing warrants and/or outstanding stock options, or public offerings of debt and/or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

 

Critical Accounting Policies

 

Management’s discussion and analysis of financial condition and results of operations is based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Management bases its estimates on historical experience and assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe there have been no material changes to the items that we disclosed as our critical accounting policies under Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our 2017 Form 10-K.

 

 13 
 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC’s”) rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 14 
 

 

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

The information required by this item is incorporated by reference from Part I, Item 1. Financial Statements, Notes to Condensed Consolidated Financial Statements, Note 6 – Litigation.

 

ITEM 1A. RISK FACTORS.

 

There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2017.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

2017 Financing

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with related parties in the aggregate principal amount of $950,000. As of June 30, 2018, the Company had drawn down the entire $950,000 under these notes.

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with accredited investors in the aggregate principal amount of $1,956,000. As of June 30, 2018, the Company had drawn down the entire $1,956,000 under these notes.

 

The Company believes that such transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act (or Rule 506 of Regulation D promulgated thereunder) as transactions by an issuer not involving a public offering.

 

For further details on the terms of the PRH Notes, refer to in our Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 23, 2018.

 

Exercise of Warrants

 

During the six months ended June 30, 2018, warrant holders exercised warrants to purchase 11,149,577 shares of common stock at a price of $0.0533 per share or $594,273.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None

 

ITEM 4. Mine Safety Disclosures.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

 15 
 

 

ITEM 6. EXHIBITS.

 

Exhibit

No.

  Description
     
10.1   Indemnification Agreement between the Company and Ed Pershing, dated April 19, 2018 (incorporated by reference to Exhibit 10.1 of the Company’s current report on Form 8-K filed on April 24, 2018).
     
10.2   Indemnification Agreement between the Company and Jack Lacey, MD, dated April 19, 2018 (incorporated by reference to Exhibit 10.2 of the Company’s current report on Form 8-K filed on April 24, 2018).
     
31.1**   Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).
     
31.2**   Certification of Interim Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).
     
32***   Certification of Principal Executive Officer and Interim Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).
     
101**   Interactive Data Files.

 

** Filed herewith.
*** Furnished herewith.

 

 16 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  PROVECTUS BIOPHARMACEUTICALS, INC.
     
August 7, 2018 By: /s/ Timothy C. Scott, Ph.D.
    Timothy C. Scott, Ph.D.
    On behalf of the registrant and as President (Principal Executive Officer)
     
  By: /s/ John R. Glass
    John R. Glass
    Interim Chief Financial Officer (Principal Financial Officer)

 

 17 
 

EX-31.1 2 ex31-1.htm

 

Exhibit 31.1

 

CERTIFICATION

 

I, Timothy C. Scott, Ph.D., certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2018 By: /s/ Timothy C. Scott, Ph.D.
    Timothy C. Scott, Ph.D.
    President (Principal Executive Officer)

 

 

 

EX-31.2 3 ex31-2.htm

 

Exhibit 31.2

 

CERTIFICATION

 

I, John R. Glass, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 7, 2018 By: /s/ John R. Glass
    John R. Glass
    Interim Chief Financial Officer (Principal Financial Officer)

 

 

 

EX-32 4 ex32.htm

 

Exhibit 32

 

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

 

Each of the undersigned, Timothy C. Scott, Ph.D., the President (principal executive officer) of Provectus Biopharmaceuticals, Inc. (the “Company”), and John R. Glass, the Interim Chief Financial Officer (principal financial officer) of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

This Certification is signed on August 7, 2018.

 

  By: /s/ Timothy C. Scott, Ph.D.
    Timothy C. Scott, Ph.D.
    President (Principal Executive Officer)

 

  By: /s/ John R. Glass
    John R. Glass
    Interim Chief Financial Officer (Principal Financial Officer)

 

 

 

 

EX-101.INS 5 pvct-20180630.xml XBRL INSTANCE FILE 0000315545 2018-01-01 2018-06-30 0000315545 2017-12-31 0000315545 2016-12-31 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2017-12-31 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2018-06-30 0000315545 PVCT:ChiefTechnologyOfficerMember 2017-02-20 2017-02-21 0000315545 PVCT:ChiefTechnologyOfficerMember 2017-02-21 0000315545 us-gaap:ExecutiveOfficerMember 2017-12-31 0000315545 PVCT:TwoThousandSeventeenFinancingMember srt:MinimumMember 2017-03-23 0000315545 PVCT:TwoThousandSeventeenFinancingMember srt:MaximumMember 2017-03-23 0000315545 PVCT:TwoThousandSeventeenFinancingMember us-gaap:SeriesDPreferredStockMember PVCT:ShareBasedCompensationAwardTrancheFinalMember 2018-06-30 0000315545 PVCT:PrhNoteMember PVCT:NonRelatedPartiesMember 2018-06-30 0000315545 us-gaap:ExecutiveOfficerMember 2016-12-26 2016-12-27 0000315545 PVCT:BibleHarrisSmithLawsuitMember 2016-11-17 0000315545 PVCT:BibleHarrisSmithLawsuitMember 2016-11-16 2016-11-17 0000315545 PVCT:RsmLawsuitMember PVCT:ExecutiveOfficerOneMember 2017-06-09 0000315545 PVCT:RsmLawsuitMember us-gaap:ExecutiveOfficerMember 2017-06-09 0000315545 PVCT:RsmLawsuitMember 2017-06-08 2017-06-09 0000315545 PVCT:PrhNoteMember PVCT:CalEnterprisesLlcMember srt:MaximumMember 2017-04-03 0000315545 PVCT:PrhNoteMember PVCT:CalEnterprisesLlcMember 2018-06-30 0000315545 2018-07-31 0000315545 PVCT:UnsecuredPromissoryNoteMember PVCT:ChiefTechnologyOfficerMember srt:MaximumMember 2017-02-21 0000315545 us-gaap:ExecutiveOfficerMember 2017-12-11 2017-12-12 0000315545 us-gaap:ExecutiveOfficerMember 2018-01-01 2018-01-31 0000315545 2018-06-30 0000315545 PVCT:PrhNoteMember PVCT:RelatedPartyMember 2018-06-30 0000315545 us-gaap:WarrantMember 2018-06-30 0000315545 us-gaap:WarrantMember 2018-01-01 2018-06-30 0000315545 PVCT:PrhNoteMember 2018-06-30 0000315545 PVCT:PrhNoteWithThirdPartyMember 2018-06-30 0000315545 us-gaap:ConvertibleNotesPayableMember 2018-01-01 2018-06-30 0000315545 2017-01-01 2017-06-30 0000315545 2017-06-30 0000315545 us-gaap:ExecutiveOfficerMember 2018-01-01 2018-06-30 0000315545 us-gaap:ExecutiveOfficerMember 2018-06-30 0000315545 2018-04-01 2018-06-30 0000315545 2017-04-01 2017-06-30 0000315545 PVCT:PrhNoteMember PVCT:NonRelatedPartiesMember 2018-01-01 2018-06-30 0000315545 PVCT:OtherCommonStockMember 2018-01-01 2018-06-30 0000315545 PVCT:TwoThousandSeventeenFinancingMember 2018-01-01 2018-06-30 0000315545 PVCT:PrhNoteMember PVCT:NonRelatedPartiesMember us-gaap:FixedMaturitiesMember 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PROVECTUS BIOPHARMACEUTICALS, INC. 0000315545 10-Q 2018-06-30 false Smaller Reporting Company PVCT 105504 1165738 130633 1127834 -10018843 -13700390 36445 43492 10145098 10480657 0.001 0.2862 0.001 25000000 25000000 240000 240000 100 100 100 100 0.001 0.001 1000000000 1000000000 370961451 383111028 370961451 383111028 2930302 4006538 987239 2252890 2304928 3694529 1342210 1050004 -5235230 -7701067 -2329449 -3302894 11725 16750 5556 8075 -4355820 -7684317 -1456208 -3294819 14057 50 -4355820 -7698374 -1456208 -3294869 379483491 367795241 381574365 370354643 7047 9422 335560 335560 533926 -183329 -126864 -115565 229962 1354439 635169 98098 3987 3500 3500 950000 3000000 1956000 2550000 14057 2018 594274 594273 25129 -37904 -0.01 -0.02 -0.00 -0.01 400416 273552 452376 974767 958296 1378952 1570347 1234787 86569 79522 455500 455500 365685 377220 3436397 3525981 3270505 3500467 728735 1363904 3999240 4864371 4456000 6412000 5000000 5950000 13455240 17226371 370962 383111 208351431 209013555 -218741236 -223097056 3436397 3525981 11149577 0.0533 0.06 1956000 2500000 2500000 950000 200000 100000 500000 2017-02-21 2500000 383111028 Q2 --12-31 455500 455500 1549043 1549043 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>1. Business Organization, Nature of Operations and Basis of Presentation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, &#8220;Provectus&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on halogenated xanthenes. Intralesional PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal cancers, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses, like psoriasis and atopic dermatitis. To date, the Company has not generated any revenues from planned principal operations. The Company&#8217;s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company&#8217;s prescription drug candidates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company&#8217;s audited consolidated financial statements included in the Company&#8217;s Form 10-K for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 23, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2. Liquidity and Going Concern</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s cash and cash equivalents were $130,633 at June 30, 2018, compared with $105,504 at December 31, 2017. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company&#8217;s business plan and develop and market its products. These circumstances raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company&#8217;s plans and its ability to continue as a going concern will depend upon the Company&#8217;s ability to develop PV-10 and PH-10 and to raise additional capital.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company plans to access capital resources through possible public or private equity offerings, including the 2017 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, but no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2017 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to June 30, 2018, the Company received aggregate Loans of $300,000 in connection with the 2017 Financing. See Note 7 &#8211; Subsequent Events.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The primary business objective of management is to build the Company into a fully integrated global biotechnology company. The Company, however, cannot assure you that it will be successful in co-developing or licensing PV-10, PH-10, or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2018 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2017 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>3. Significant Accounting Policies</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company&#8217;s significant accounting policies are disclosed in Note 3 &#8211; Significant Accounting Policies in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017. Since the date of the Annual Report, there have been no material changes to the Company&#8217;s significant accounting policies, except as disclosed below.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In May 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-09, &#8220;Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods beginning after December 15, 2017 for share-based payment awards modified on or after the adoption date. The adoption of this ASU did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2018, the FASB issued ASU No. 2018-05, &#8220;Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118&#8221; (&#8220;ASU 2018-05&#8221;). ASU 2018-05 adds various &#8220;SEC&#8221; paragraphs pursuant to the issuance of the December 2017 SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (&#8220;SAB 118&#8221;), which was effective immediately. The SEC issued SAB 118 to address concerns about reporting entities&#8217; ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Cuts and Jobs Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Tax Cuts and Jobs Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has accounted for the tax effects of the Tax Cuts and Jobs Act under the guidance of SAB 118 and does not believe that the adoption of ASU 2018-05 will have a material impact on the Company&#8217;s condensed consolidated financial statements or disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07, &#8220;Compensation &#8212; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting&#8221; (&#8220;ASU 2018-07&#8221;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation &#8212; Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity &#8212; Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the Company&#8217;s condensed consolidated financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>4. Convertible Notes Payable</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company&#8217;s stockholders (the &#8220;PRH Group&#8221;), which was amended and restated effective as of March 19, 2017 (the &#8220;Term Sheet&#8221;) that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $10,000,000 and maximum of $20,000,000 (the &#8220;2017 Financing&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The 2017 Financing is in the form of secured convertible loans (the &#8220;Loans&#8221;) from the PRH Group or other investors in the 2017 Financing (the &#8220;Investors&#8221;). The Loans are evidenced by secured convertible promissory notes (individually a &#8220;PRH Note&#8221; and collectively, the &#8220;PRH Notes&#8221;) from the Company to the PRH Group or the investors.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The principal amounts of the PRH Notes and the interest payable under the Loan would automatically convert into shares of the Company&#8217;s Series D Preferred Stock at a price per share equal to $0.2862 effective on the 18-month anniversary of the funding of the final tranche of the 2017 Financing subject to certain exceptions if the Company&#8217;s Board designates such series of preferred stock in the future.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018, and through the date of filing, the Series D Preferred Stock had not been designated by the Board and, accordingly, the PRH Notes are not convertible into shares of Series D Preferred Stock. As a result, the Company did not analyze the Loan for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the PRH Notes were not convertible as of their respective dates of issuance or as of June 30, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As of June 30, 2018, the Company had received aggregate Loans of $12,362,000 in connection with the 2017 Financing from both non-related and related parties. For further details on the terms of the PRH Notes, refer to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 23, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Convertible Notes Payable &#8211; Related Parties</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On February 21, 2017, the Company issued a promissory note in favor of Eric A. Wachter, Ph.D., the Company&#8217;s Chief Technology Officer (&#8220;Wachter&#8221;), evidencing an unsecured loan from Wachter to the Company in the original principal amount of up to $2,500,000 (the &#8220;Wachter Note&#8221;). Interest accrues on the outstanding balance of the Wachter Note at six percent (6%) per annum calculated on a 360-day basis.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On April 3, 2017, the Company entered into a PRH Note with Cal Enterprises LLC, a Nevada limited liability company, an affiliate of Dominic Rodrigues, a director of the Company, in the principal amount of up to $2,500,000. As of June 30, 2018, the Company had borrowed the entire $2,500,000 under this note.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the six months ended June 30, 2018, the Company amended the above notes to modify the maturity date from 24 months to 18 months in order to be consistent with the other outstanding PRH Notes. The actual maturity dates will be determined after the completion of the 2017 Financing.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the six months ended June 30, 2018, the Company entered into additional PRH Notes with related parties in the aggregate principal amount of $950,000. As of June 30, 2018, the Company had drawn down the entire $950,000 under these notes.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Convertible Notes Payable &#8211; Non-Related Parties</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company entered into additional PRH Notes with accredited investors in the aggregate principal amount of $1,956,000. As of June 30, 2018, the Company had drawn down the entire $1,956,000 under these notes. Included in the $1,956,000 is one PRH note totaling $500,000 with terms of principal and interest due twenty-four (24) months from date of signing. This note will mature in June 2020.&#160;</p> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>5. Stockholders&#8217; Deficiency</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Exercise of Warrants</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30,2018, warrant holders exercised warrants to purchase an aggregate of 11,149,577 shares of commons stock at a price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $594,273 and issued 11,149,577 shares of common stock to the warrant holders.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Other Common Stock Issuances</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the six months ended June 30, 2018, the Company issued 1,000,000 shares of common stock in payment of services with a grant date fair value of $80,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">As the fair market&#160;value&#160;of the service was not readily determinable, the service was valued based on the fair market value of the stock at&#160;grant&#160;date.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>6. Litigation</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Culpepper Travel Expenses and Related Collection Efforts</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On December 27, 2016, the Company&#8217;s Board of Directors unanimously voted to terminate Culpepper, effective immediately, from all positions he held with the Company and each of its subsidiaries, including interim Chief Executive Officer and Chief Operating Officer of the Company, &#8220;for cause&#8221;, in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the &#8220;Culpepper Employment Agreement&#8221;) based on the results of the investigation conducted by the Audit Committee of the Board of Directors regarding improper expense reimbursements to Culpepper.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Audit Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Audit Committee in conducting the investigation. The Audit Committee found that Culpepper received $294,255 in expense reimbursements that were unsubstantiated or otherwise improper. The Company seeks to recover from Culpepper the entire $294,255 in expense reimbursements, as well as all attorney&#8217;s fees and auditors&#8217;/experts&#8217; fees incurred by the Company in connection with the examination of his expense reimbursements. On December 12, 2017, Culpepper agreed to an order by the SEC to pay disgorgement of $140,115, and prejudgment interest of $12,261, for a total of $152,376, to the Company within 30 days. The Company received the payment of $152,376 in January 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company takes the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination &#8220;for cause&#8221; as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Derivative Lawsuit Settlement such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper&#8217;s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,051,083 as of June 30, 2018 and December 31, 2017, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys&#8217; fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Culpepper disputes that he was terminated &#8220;for cause&#8221; under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating both Culpepper&#8217;s claim for severance against Provectus and Provectus&#8217; claims against Culpepper for improper expense reimbursements and amounts Culpepper owes Provectus under the Derivative Lawsuit Settlement (the &#8220;Culpepper Arbitration&#8221;). The Culpepper Arbitration hearing was held from May 15, 2018 through May 18, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On July 12, 2018, the arbitrator issued an interim award in favor of the Company, the terms of which are confidential pursuant to the terms of the Culpepper Employment Agreement and instructed the parties that a final award is forthcoming.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>The Bible Harris Smith Lawsuit</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 17, 2016, the Company filed a lawsuit in the Circuit Court for Knox County, Tennessee against Bible Harris Smith PC (&#8220;BHS&#8221;) for professional negligence, common law negligence and breach of fiduciary duty arising from accounting services provided by BHS to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company further alleges that had BHS provided competent accounting and tax preparation services, it would have discovered Dees&#8217; failure to submit back-up documentation supporting the advanced travel funds at the inception of Dees&#8217; conduct, and prevented the misuse of these and future funds. The Company has made a claim for damages against BHS in an amount in excess of $3 million. The complaint against BHS has been filed and served, an answer has been received, and the parties are in the midst of discovery. BHS filed a Motion for Summary Judgment, which was denied in full by the Court on June 21, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>The RSM Lawsuit</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On June 9, 2017, the Company filed a lawsuit in the Circuit Court of Mecklenburg County, North Carolina against RSM USA LLP (&#8220;RSM&#8221;) for professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation and breach of fiduciary duty arising from accounting, internal auditing and consulting services provided by RSM to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company similarly alleges that Culpepper received $294,255 in travel expense reimbursements and advances that were unsubstantiated. The Company further alleges that had RSM provided competent accounting, internal audit and consulting services, it would have discovered Dees&#8217; and Culpepper&#8217;s conduct at its inception and prevented the misuse of these and future funds. The Company has made a claim for damages against RSM in an amount in excess of $10 million. The Complaint against RSM has been filed and RSM has moved to dismiss the Complaint. The motion to dismiss has been briefed and argued and the parties are awaiting a ruling.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>The BDO Matter</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On November 16, 2017, the Company filed a demand for arbitration with the American Arbitration Association that&#160;alleged&#160;professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation, and breach of fiduciary duty by the Company&#8217;s former external audit firm, BDO USA LLP (&#8220;BDO&#8221;), arising from accounting, external auditing, and consulting services provided by BDO related to travel and expense advances and reimbursements received by Dees and former Company executive Culpepper. During the quarter ended June 30, 2018, this matter&#160;was resolved pursuant to a settlement between the parties, the terms of which are confidential.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Subsequent to June 30, 2018, the proceeds from the settlement were received.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7. Subsequent Events</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Convertible Notes Payable</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2018, the Company entered into a PRH Note with a related party in the principal amount of $200,000 and a PRH Note with a non-related party in the principal amount of $100,000. The Company has received the proceeds of $300,000 relating to these notes.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><i>Recent Accounting Pronouncements</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In May 2017, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-09, &#8220;Compensation&#8212;Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; (&#8220;ASU 2017-09&#8221;). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods beginning after December 15, 2017 for share-based payment awards modified on or after the adoption date. The adoption of this ASU did not have a material impact on the Company&#8217;s condensed consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In July 2017, the FASB issued ASU No. 2017-11, &#8220;Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features&#8221; (&#8220;ASU 2017-11&#8221;). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is re-measured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (&#8220;EPS&#8221;) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">In March 2018, the FASB issued ASU No. 2018-05, &#8220;Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118&#8221; (&#8220;ASU 2018-05&#8221;). ASU 2018-05 adds various &#8220;SEC&#8221; paragraphs pursuant to the issuance of the December 2017 SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (&#8220;SAB 118&#8221;), which was effective immediately. The SEC issued SAB 118 to address concerns about reporting entities&#8217; ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Cuts and Jobs Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Tax Cuts and Jobs Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has accounted for the tax effects of the Tax Cuts and Jobs Act under the guidance of SAB 118 and does not believe that the adoption of ASU 2018-05 will have a material impact on the Company&#8217;s condensed consolidated financial statements or disclosures.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07, &#8220;Compensation &#8212; Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting&#8221; (&#8220;ASU 2018-07&#8221;). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation &#8212; Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity &#8212; Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company&#8217;s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the Company&#8217;s condensed consolidated financial statements.</p> Calculated on a 360-day basis 1956000 950000 11149577 -3475145 -5587904 3500274 5550000 825000 825000 42685 42685 1595 80000 80000 2020-06-30 294255 The Company seeks to recover from Culpepper the entire $294,255 in expense reimbursements 140115 12261 152376 152376 2240000 227750 2051083 2051083 2400000 294255 2400000 10000000 3000000 300000 300000 12362000 1000000 10000000 20000000 EX-101.SCH 6 pvct-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Stockholders' Deficiency link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Litigation link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Stockholders' Deficiency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Litigation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pvct-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pvct-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pvct-20180630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series B Convertible Preferred Stock [Member] Related Party [Axis] Chief Technology Officer [Member] Executive Officer [Member] Plan Name [Axis] 2017 Financing [Member] Range [Axis] Minimum [Member] Maximum [Member] Series D Preferred Stock [Member] Vesting [Axis] Final Tranche [Member] Debt Instrument [Axis] PRH Note [Member] Scenario [Axis] Non-Related Parties [Member] Litigation Case [Axis] Bible Harris Smith Lawsuit [Member] RSM Lawsuit [Member] Executive Officer One [Member] Cal Enterprises LLC [Member] Short-term Debt, Type [Axis] Unsecured Promissory Note [Member] Related Party [Member] Equity Components [Axis] Warrant [Member] PRH Note with Third Party [Member] Convertible Notes Payable [Member] Other Common Stock [Member] Investment Type [Axis] Notes Due in Twenty Four Months [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Short-term receivables - settlement and other Prepaid expenses Total Current Assets Equipment and furnishings, less accumulated depreciation of $43,492 and $36,445, respectively Patents, net of accumulated amortization of $10,480,657 and $10,145,098, respectively Long-term receivable - reimbursable legal fees, net of reserve for uncollectibility of $455,500 Long-term receivable - settlement, net of discount and reserve for uncollectibility of $1,549,043 Total Assets Liabilities and Stockholders' Deficiency Current Liabilities: Accounts payable - trade Other accrued expenses Total Current Liabilities Convertible notes payable Convertible notes payable - related parties Total Liabilities Commitments and contingencies Stockholders' Deficiency: Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2018 and December 31, 2017; aggregate liquidation preference of $3,500 at June 30, 2018 and December 31, 2017 Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 383,111,028 and 370,961,451 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total Stockholder's Deficiency Total Liabilities and Stockholders' Deficiency Statement [Table] Statement [Line Items] Accumulated depreciation on equipment and furnishings Accumulated amortization on patents Reimbursable legal fees, reserve for uncollectibility Settlement, discount and reserve for uncollectibility Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares designated Preferred stock, shares issued Preferred stock, shares outstanding Aggregate liquidation preference Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development General and administrative Total Operating Loss Gain on settlement of lawsuit Research and development tax credit Investment income Net Loss Dividend paid-in kind to preferred shareholders Net Loss Applicable to Common Shareholders Basic and Diluted Loss Per Common Share Weighted Average Number of Common Shares Outstanding - Basic and Diluted Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Amortization of patents Issuance of stock for services Changes in operating assets and liabilities Settlement receivable Other current assets Accounts payable - trade Other accrued expenses Net Cash Used In Operating Activities Cash Flows From Financing Activities Proceeds from issuance of convertible notes payable Proceeds from issuance of convertible notes payable - related party Proceeds from exercise of warrants Net Cash Provided By Financing Activities Net Change In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosures of Cash Flow Information: Non-cash investing and financing activities: Conversion of preferred stock into common stock Dividend paid-in kind to preferred shareholders Issuance in-kind of preferred stock dividends Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Organization, Nature of Operations and Basis of Presentation Liquidity and Going Concern Accounting Policies [Abstract] Significant Accounting Policies Debt Disclosure [Abstract] Convertible Notes Payable Equity [Abstract] Stockholders' Deficiency Commitments and Contingencies Disclosure [Abstract] Litigation Subsequent Events [Abstract] Subsequent Events Recent Accounting Pronouncements Loans received in connection with financing Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Financing arrangement amount Preferred stock, par or stated value per share Promissory note issuance date Principal amount borrowed Interest rate Interest payments Borrowed under note Drawn down under the notes value Debt maturity date Schedule of Stock by Class [Table] Class of Stock [Line Items] Warrant to purchase shares of common stock Exercise price of warrant Proceeds from warrant exercises Number of shares issued upon warrant exercise Number of common stock shares issued for service Number of common stock shares issued for service, grant date fair value Loss Contingencies [Table] Loss Contingencies [Line Items] Title of Individual [Axis] Report Date [Axis] Travel expense reimbursements and advances without receipt Expense reimbursements, description Pay disgorgement amount Prejudgment interest amount Aggregate value of legal settlements Company received the payment Damages sought to be receivable Litigation cost Reserve for litigation Loss contingency amount advanced or reimbursed Amount of damages awarded Loss contingency amount of remaining obligation Subsequent Event Type [Axis] Principal amount Proceeds from related party notes BDO Lawsuit [Member] Bible Harris Smith Lawsuit. Cal Enterprises LLC [Member] Chief Technology Officer. Drawndown under the notes value. Executive Officer One [Member] Issuance in-kind of preferred stock dividends. Long term receivable reimbursable legal fees. Non-Related Parties [Member] Number of shares issued upon warrant exercise. Preferred stock, shares designated. PRH Note [Member] PRH Note with Third Party [Member] Proceeds from issuance of convertible notes payable - related parties. Reimbursable legal fees, reserve for uncollectibility. RelatedParty [Member] RSM Lawsuit [Member] Series B Convertible Preferred Stock [Member] Settlement, discount and reserve for uncollectibility. Final Tranche [Member] Subsequent to March 31, 2018 [Member] 2017 Financing [Member] Unsecured Promissory Note [Member] Wachter Note [Member] Warrant Holders [Member] Research and development tax credit. Dividend paid-in kind to preferred shareholders. Subsequent to June 30, 2018 [Membe Other Common Stock [Member] Reimbursements and advances to travel expenses without receipt. Expense reimbursements, description. Aggregate value of legal settlements. Loss contingency amount reimbursed. Loss contingency amount of remaining obligation. Financing arrangement amount. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Income (Loss) Dividends, Preferred Stock, Paid-in-kind Net Income (Loss) Available to Common Stockholders, Basic Increase (Decrease) in Receivables Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable, Trade Increase (Decrease) in Other Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) EX-101.PRE 10 pvct-20180630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2018
Jul. 31, 2018
Document And Entity Information    
Entity Registrant Name PROVECTUS BIOPHARMACEUTICALS, INC.  
Entity Central Index Key 0000315545  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   383,111,028
Trading Symbol PVCT  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2018  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current Assets:    
Cash and cash equivalents $ 130,633 $ 105,504
Short-term receivables - settlement and other 974,767 452,376
Prepaid expenses 273,552 400,416
Total Current Assets 1,378,952 958,296
Equipment and furnishings, less accumulated depreciation of $43,492 and $36,445, respectively 79,522 86,569
Patents, net of accumulated amortization of $10,480,657 and $10,145,098, respectively 1,234,787 1,570,347
Long-term receivable - reimbursable legal fees, net of reserve for uncollectibility of $455,500 455,500 455,500
Long-term receivable - settlement, net of discount and reserve for uncollectibility of $1,549,043 377,220 365,685
Total Assets 3,525,981 3,436,397
Current Liabilities:    
Accounts payable - trade 3,500,467 3,270,505
Other accrued expenses 1,363,904 728,735
Total Current Liabilities 4,864,371 3,999,240
Convertible notes payable 6,412,000 4,456,000
Convertible notes payable - related parties 5,950,000 5,000,000
Total Liabilities 17,226,371 13,455,240
Commitments and contingencies
Stockholders' Deficiency:    
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2018 and December 31, 2017; aggregate liquidation preference of $3,500 at June 30, 2018 and December 31, 2017
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 383,111,028 and 370,961,451 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively 383,111 370,962
Additional paid-in capital 209,013,555 208,351,431
Accumulated deficit (223,097,056) (218,741,236)
Total Stockholder's Deficiency (13,700,390) (10,018,843)
Total Liabilities and Stockholders' Deficiency $ 3,525,981 $ 3,436,397
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Accumulated depreciation on equipment and furnishings $ 43,492 $ 36,445
Accumulated amortization on patents 10,480,657 10,145,098
Reimbursable legal fees, reserve for uncollectibility 455,500 455,500
Settlement, discount and reserve for uncollectibility $ 1,549,043 $ 1,549,043
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 25,000,000 25,000,000
Preferred stock, shares issued 100 100
Preferred stock, shares outstanding 100 100
Aggregate liquidation preference $ 3,500 $ 3,500
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 1,000,000,000 1,000,000,000
Common stock, shares issued 383,111,028 370,961,451
Common stock, shares outstanding 383,111,028 370,961,451
Series B Convertible Preferred Stock [Member]    
Preferred stock, shares designated 240,000 240,000
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Operating Expenses:        
Research and development $ 987,239 $ 2,252,890 $ 2,930,302 $ 4,006,538
General and administrative 1,342,210 1,050,004 2,304,928 3,694,529
Total Operating Loss (2,329,449) (3,302,894) (5,235,230) (7,701,067)
Gain on settlement of lawsuit 825,000 825,000
Research and development tax credit 42,685 42,685
Investment income 5,556 8,075 11,725 16,750
Net Loss (1,456,208) (3,294,819) (4,355,820) (7,684,317)
Dividend paid-in kind to preferred shareholders (50) (14,057)
Net Loss Applicable to Common Shareholders $ (1,456,208) $ (3,294,869) $ (4,355,820) $ (7,698,374)
Basic and Diluted Loss Per Common Share $ (0.00) $ (0.01) $ (0.01) $ (0.02)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted 381,574,365 370,354,643 379,483,491 367,795,241
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash Flows From Operating Activities    
Net loss $ (4,355,820) $ (7,684,317)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 7,047 9,422
Amortization of patents 335,560 335,560
Issuance of stock for services 80,000
Changes in operating assets and liabilities    
Settlement receivable (533,926) 183,329
Other current assets 126,864 115,565
Accounts payable - trade 229,962 1,354,439
Other accrued expenses 635,169 98,098
Net Cash Used In Operating Activities (3,475,145) (5,587,904)
Cash Flows From Financing Activities    
Proceeds from issuance of convertible notes payable 1,956,000 2,550,000
Proceeds from issuance of convertible notes payable - related party 950,000 3,000,000
Proceeds from exercise of warrants 594,274
Net Cash Provided By Financing Activities 3,500,274 5,550,000
Net Change In Cash and Cash Equivalents 25,129 (37,904)
Cash and Cash Equivalents, Beginning of Period 105,504 1,165,738
Cash and Cash Equivalents, End of Period 130,633 1,127,834
Non-cash investing and financing activities:    
Conversion of preferred stock into common stock 3,987
Dividend paid-in kind to preferred shareholders 1,595
Issuance in-kind of preferred stock dividends $ 14,057
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Business Organization, Nature of Operations and Basis of Presentation
6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Organization, Nature of Operations and Basis of Presentation

1. Business Organization, Nature of Operations and Basis of Presentation

 

Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company developing a new class of drugs for oncology and dermatology based on halogenated xanthenes. Intralesional PV-10 is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal cancers, and preclinical study for pediatric cancers. Topical PH-10 is undergoing clinical study for inflammatory dermatoses, like psoriasis and atopic dermatitis. To date, the Company has not generated any revenues from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 23, 2018. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018.

XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern
6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity and Going Concern

2. Liquidity and Going Concern

 

The Company’s cash and cash equivalents were $130,633 at June 30, 2018, compared with $105,504 at December 31, 2017. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop PV-10 and PH-10 and to raise additional capital.

 

The Company plans to access capital resources through possible public or private equity offerings, including the 2017 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, PV-10 and PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, but no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2017 Financing or otherwise, it will not be able to pay its obligations as they become due. Subsequent to June 30, 2018, the Company received aggregate Loans of $300,000 in connection with the 2017 Financing. See Note 7 – Subsequent Events.

  

The primary business objective of management is to build the Company into a fully integrated global biotechnology company. The Company, however, cannot assure you that it will be successful in co-developing or licensing PV-10, PH-10, or any other halogenated xanthene-based drug candidate developed by the Company, or entering into any financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2018 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2017 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot provide assurance that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies
6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Significant Accounting Policies

3. Significant Accounting Policies

 

The Company’s significant accounting policies are disclosed in Note 3 – Significant Accounting Policies in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Since the date of the Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

 

Recent Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods beginning after December 15, 2017 for share-based payment awards modified on or after the adoption date. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

 

In March 2018, the FASB issued ASU No. 2018-05, “Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118” (“ASU 2018-05”). ASU 2018-05 adds various “SEC” paragraphs pursuant to the issuance of the December 2017 SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which was effective immediately. The SEC issued SAB 118 to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Cuts and Jobs Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Tax Cuts and Jobs Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has accounted for the tax effects of the Tax Cuts and Jobs Act under the guidance of SAB 118 and does not believe that the adoption of ASU 2018-05 will have a material impact on the Company’s condensed consolidated financial statements or disclosures.

  

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the Company’s condensed consolidated financial statements.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable
6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Convertible Notes Payable

4. Convertible Notes Payable

 

On March 23, 2017, the Company entered into an exclusive Definitive Financing Commitment Term Sheet with a group of the Company’s stockholders (the “PRH Group”), which was amended and restated effective as of March 19, 2017 (the “Term Sheet”) that set forth the terms on which the PRH Group would use their best efforts to arrange for a financing of a minimum of $10,000,000 and maximum of $20,000,000 (the “2017 Financing”).

 

The 2017 Financing is in the form of secured convertible loans (the “Loans”) from the PRH Group or other investors in the 2017 Financing (the “Investors”). The Loans are evidenced by secured convertible promissory notes (individually a “PRH Note” and collectively, the “PRH Notes”) from the Company to the PRH Group or the investors.

 

The principal amounts of the PRH Notes and the interest payable under the Loan would automatically convert into shares of the Company’s Series D Preferred Stock at a price per share equal to $0.2862 effective on the 18-month anniversary of the funding of the final tranche of the 2017 Financing subject to certain exceptions if the Company’s Board designates such series of preferred stock in the future.

 

As of June 30, 2018, and through the date of filing, the Series D Preferred Stock had not been designated by the Board and, accordingly, the PRH Notes are not convertible into shares of Series D Preferred Stock. As a result, the Company did not analyze the Loan for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the PRH Notes were not convertible as of their respective dates of issuance or as of June 30, 2018.

 

As of June 30, 2018, the Company had received aggregate Loans of $12,362,000 in connection with the 2017 Financing from both non-related and related parties. For further details on the terms of the PRH Notes, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the SEC on March 23, 2018.

 

Convertible Notes Payable – Related Parties

 

On February 21, 2017, the Company issued a promissory note in favor of Eric A. Wachter, Ph.D., the Company’s Chief Technology Officer (“Wachter”), evidencing an unsecured loan from Wachter to the Company in the original principal amount of up to $2,500,000 (the “Wachter Note”). Interest accrues on the outstanding balance of the Wachter Note at six percent (6%) per annum calculated on a 360-day basis.

 

On April 3, 2017, the Company entered into a PRH Note with Cal Enterprises LLC, a Nevada limited liability company, an affiliate of Dominic Rodrigues, a director of the Company, in the principal amount of up to $2,500,000. As of June 30, 2018, the Company had borrowed the entire $2,500,000 under this note.

 

During the six months ended June 30, 2018, the Company amended the above notes to modify the maturity date from 24 months to 18 months in order to be consistent with the other outstanding PRH Notes. The actual maturity dates will be determined after the completion of the 2017 Financing.

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with related parties in the aggregate principal amount of $950,000. As of June 30, 2018, the Company had drawn down the entire $950,000 under these notes.

 

Convertible Notes Payable – Non-Related Parties

 

During the six months ended June 30, 2018, the Company entered into additional PRH Notes with accredited investors in the aggregate principal amount of $1,956,000. As of June 30, 2018, the Company had drawn down the entire $1,956,000 under these notes. Included in the $1,956,000 is one PRH note totaling $500,000 with terms of principal and interest due twenty-four (24) months from date of signing. This note will mature in June 2020. 

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Deficiency
6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Stockholders' Deficiency

5. Stockholders’ Deficiency

 

Exercise of Warrants

 

During the six months ended June 30,2018, warrant holders exercised warrants to purchase an aggregate of 11,149,577 shares of commons stock at a price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $594,273 and issued 11,149,577 shares of common stock to the warrant holders.

 

Other Common Stock Issuances

 

During the six months ended June 30, 2018, the Company issued 1,000,000 shares of common stock in payment of services with a grant date fair value of $80,000.

 

As the fair market value of the service was not readily determinable, the service was valued based on the fair market value of the stock at grant date.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Litigation
6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Litigation

6. Litigation

 

Culpepper Travel Expenses and Related Collection Efforts

 

On December 27, 2016, the Company’s Board of Directors unanimously voted to terminate Culpepper, effective immediately, from all positions he held with the Company and each of its subsidiaries, including interim Chief Executive Officer and Chief Operating Officer of the Company, “for cause”, in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”) based on the results of the investigation conducted by the Audit Committee of the Board of Directors regarding improper expense reimbursements to Culpepper.

 

The Audit Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Audit Committee in conducting the investigation. The Audit Committee found that Culpepper received $294,255 in expense reimbursements that were unsubstantiated or otherwise improper. The Company seeks to recover from Culpepper the entire $294,255 in expense reimbursements, as well as all attorney’s fees and auditors’/experts’ fees incurred by the Company in connection with the examination of his expense reimbursements. On December 12, 2017, Culpepper agreed to an order by the SEC to pay disgorgement of $140,115, and prejudgment interest of $12,261, for a total of $152,376, to the Company within 30 days. The Company received the payment of $152,376 in January 2018.

 

The Company takes the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Derivative Lawsuit Settlement such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,051,083 as of June 30, 2018 and December 31, 2017, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount.

 

Culpepper disputes that he was terminated “for cause” under the Culpepper Employment Agreement. Pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute on June 28, 2017. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating both Culpepper’s claim for severance against Provectus and Provectus’ claims against Culpepper for improper expense reimbursements and amounts Culpepper owes Provectus under the Derivative Lawsuit Settlement (the “Culpepper Arbitration”). The Culpepper Arbitration hearing was held from May 15, 2018 through May 18, 2018.

 

On July 12, 2018, the arbitrator issued an interim award in favor of the Company, the terms of which are confidential pursuant to the terms of the Culpepper Employment Agreement and instructed the parties that a final award is forthcoming.

 

The Bible Harris Smith Lawsuit

 

On November 17, 2016, the Company filed a lawsuit in the Circuit Court for Knox County, Tennessee against Bible Harris Smith PC (“BHS”) for professional negligence, common law negligence and breach of fiduciary duty arising from accounting services provided by BHS to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company further alleges that had BHS provided competent accounting and tax preparation services, it would have discovered Dees’ failure to submit back-up documentation supporting the advanced travel funds at the inception of Dees’ conduct, and prevented the misuse of these and future funds. The Company has made a claim for damages against BHS in an amount in excess of $3 million. The complaint against BHS has been filed and served, an answer has been received, and the parties are in the midst of discovery. BHS filed a Motion for Summary Judgment, which was denied in full by the Court on June 21, 2018.

 

The RSM Lawsuit

 

On June 9, 2017, the Company filed a lawsuit in the Circuit Court of Mecklenburg County, North Carolina against RSM USA LLP (“RSM”) for professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation and breach of fiduciary duty arising from accounting, internal auditing and consulting services provided by RSM to the Company. The Company alleges that between 2013 and 2015, Dees received approximately $2.4 million in advanced or reimbursed travel and entertainment expenses from the Company and that Dees did not submit back-up documentation in support of substantially all of the advances he received purportedly for future travel and entertainment expenses. The Company similarly alleges that Culpepper received $294,255 in travel expense reimbursements and advances that were unsubstantiated. The Company further alleges that had RSM provided competent accounting, internal audit and consulting services, it would have discovered Dees’ and Culpepper’s conduct at its inception and prevented the misuse of these and future funds. The Company has made a claim for damages against RSM in an amount in excess of $10 million. The Complaint against RSM has been filed and RSM has moved to dismiss the Complaint. The motion to dismiss has been briefed and argued and the parties are awaiting a ruling.

 

The BDO Matter

 

On November 16, 2017, the Company filed a demand for arbitration with the American Arbitration Association that alleged professional negligence, common law negligence, gross negligence, intentional misrepresentation, negligent misrepresentation, and breach of fiduciary duty by the Company’s former external audit firm, BDO USA LLP (“BDO”), arising from accounting, external auditing, and consulting services provided by BDO related to travel and expense advances and reimbursements received by Dees and former Company executive Culpepper. During the quarter ended June 30, 2018, this matter was resolved pursuant to a settlement between the parties, the terms of which are confidential.

 

Subsequent to June 30, 2018, the proceeds from the settlement were received.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

7. Subsequent Events

 

Convertible Notes Payable

 

Subsequent to June 30, 2018, the Company entered into a PRH Note with a related party in the principal amount of $200,000 and a PRH Note with a non-related party in the principal amount of $100,000. The Company has received the proceeds of $300,000 relating to these notes.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Significant Accounting Policies (Policies)
6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASU 2017-09”). ASU 2017-09 provides clarity on the accounting for modifications of stock-based awards. ASU 2017-09 requires adoption on a prospective basis in the annual and interim periods beginning after December 15, 2017 for share-based payment awards modified on or after the adoption date. The adoption of this ASU did not have a material impact on the Company’s condensed consolidated financial statements.

 

In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is re-measured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, including adoption in any interim period.

 

In March 2018, the FASB issued ASU No. 2018-05, “Income Taxes (Topic 740), Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118” (“ASU 2018-05”). ASU 2018-05 adds various “SEC” paragraphs pursuant to the issuance of the December 2017 SEC Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which was effective immediately. The SEC issued SAB 118 to address concerns about reporting entities’ ability to timely comply with the accounting requirements to recognize all of the effects of the Tax Cuts and Jobs Act in the period of enactment. SAB 118 allows disclosure that timely determination of some or all of the income tax effects from the Tax Cuts and Jobs Act are incomplete by the due date of the financial statements and if possible to provide a reasonable estimate. The Company has accounted for the tax effects of the Tax Cuts and Jobs Act under the guidance of SAB 118 and does not believe that the adoption of ASU 2018-05 will have a material impact on the Company’s condensed consolidated financial statements or disclosures.

 

In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company is currently evaluating ASU 2018-07 and its impact on the Company’s condensed consolidated financial statements.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Liquidity and Going Concern (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Jun. 30, 2017
Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 130,633 $ 105,504 $ 1,127,834 $ 1,165,738
Loans received in connection with financing $ 300,000      
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable (Details Narrative) - USD ($)
6 Months Ended
Feb. 21, 2017
Jun. 30, 2018
Dec. 31, 2017
Apr. 03, 2017
Mar. 23, 2017
Related Party Transaction [Line Items]          
Preferred stock, par or stated value per share   $ 0.001 $ 0.001    
Loans received in connection with financing   $ 300,000      
PRH Note [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed   200,000      
Chief Technology Officer [Member]          
Related Party Transaction [Line Items]          
Promissory note issuance date Feb. 21, 2017        
Interest rate 6.00%        
Interest payments Calculated on a 360-day basis        
Cal Enterprises LLC [Member] | PRH Note [Member]          
Related Party Transaction [Line Items]          
Borrowed under note   2,500,000      
Related Party [Member] | PRH Note [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed   950,000      
Drawn down under the notes value   950,000      
Non-Related Parties [Member] | PRH Note [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed   1,956,000      
Drawn down under the notes value   $ 1,956,000      
Debt maturity date   Jun. 30, 2020      
Non-Related Parties [Member] | PRH Note [Member] | Notes Due in Twenty Four Months [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed   $ 500,000      
Maximum [Member] | Chief Technology Officer [Member] | Unsecured Promissory Note [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed $ 2,500,000        
Maximum [Member] | Cal Enterprises LLC [Member] | PRH Note [Member]          
Related Party Transaction [Line Items]          
Principal amount borrowed       $ 2,500,000  
2017 Financing [Member]          
Related Party Transaction [Line Items]          
Loans received in connection with financing   $ 12,362,000      
2017 Financing [Member] | Series D Preferred Stock [Member] | Final Tranche [Member]          
Related Party Transaction [Line Items]          
Preferred stock, par or stated value per share   $ 0.2862      
2017 Financing [Member] | Minimum [Member]          
Related Party Transaction [Line Items]          
Financing arrangement amount         $ 10,000,000
2017 Financing [Member] | Maximum [Member]          
Related Party Transaction [Line Items]          
Financing arrangement amount         $ 20,000,000
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Deficiency (Details Narrative) - USD ($)
6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Class of Stock [Line Items]    
Proceeds from warrant exercises $ 594,274
Number of common stock shares issued for service, grant date fair value $ 80,000
Warrant [Member]    
Class of Stock [Line Items]    
Warrant to purchase shares of common stock 11,149,577  
Exercise price of warrant $ 0.0533  
Proceeds from warrant exercises $ 594,273  
Number of shares issued upon warrant exercise 11,149,577  
Other Common Stock [Member]    
Class of Stock [Line Items]    
Number of common stock shares issued for service 1,000,000  
Number of common stock shares issued for service, grant date fair value $ 80,000  
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Litigation (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended
Dec. 12, 2017
Jun. 09, 2017
Dec. 27, 2016
Nov. 17, 2016
Jan. 31, 2018
Jun. 30, 2018
Dec. 31, 2017
Bible Harris Smith Lawsuit [Member]              
Loss Contingencies [Line Items]              
Loss contingency amount advanced or reimbursed       $ 2,400,000      
Amount of damages awarded       $ 3,000,000      
RSM Lawsuit [Member]              
Loss Contingencies [Line Items]              
Loss contingency amount of remaining obligation   $ 10,000,000          
Executive Officer [Member]              
Loss Contingencies [Line Items]              
Travel expense reimbursements and advances without receipt     $ 294,255        
Expense reimbursements, description     The Company seeks to recover from Culpepper the entire $294,255 in expense reimbursements        
Pay disgorgement amount $ 140,115            
Prejudgment interest amount 12,261            
Aggregate value of legal settlements $ 152,376            
Company received the payment         $ 152,376    
Damages sought to be receivable           $ 2,240,000  
Litigation cost           227,750  
Reserve for litigation           $ 2,051,083 $ 2,051,083
Executive Officer [Member] | RSM Lawsuit [Member]              
Loss Contingencies [Line Items]              
Loss contingency amount advanced or reimbursed   2,400,000          
Executive Officer One [Member] | RSM Lawsuit [Member]              
Loss Contingencies [Line Items]              
Loss contingency amount advanced or reimbursed   $ 294,255          
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details Narrative)
6 Months Ended
Jun. 30, 2018
USD ($)
PRH Note with Third Party [Member]  
Principal amount $ 100,000
PRH Note [Member]  
Principal amount 200,000
Convertible Notes Payable [Member]  
Proceeds from related party notes $ 300,000
EXCEL 29 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 30 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 31 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 41 108 1 false 21 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://provectusbio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://provectusbio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://provectusbio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://provectusbio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://provectusbio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation Sheet http://provectusbio.com/role/BusinessOrganizationNatureOfOperationsAndBasisOfPresentation Business Organization, Nature of Operations and Basis of Presentation Notes 6 false false R7.htm 00000007 - Disclosure - Liquidity and Going Concern Sheet http://provectusbio.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Significant Accounting Policies Sheet http://provectusbio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Convertible Notes Payable Notes http://provectusbio.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - Stockholders' Deficiency Sheet http://provectusbio.com/role/StockholdersDeficiency Stockholders' Deficiency Notes 10 false false R11.htm 00000011 - Disclosure - Litigation Sheet http://provectusbio.com/role/Litigation Litigation Notes 11 false false R12.htm 00000012 - Disclosure - Subsequent Events Sheet http://provectusbio.com/role/SubsequentEvents Subsequent Events Notes 12 false false R13.htm 00000013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://provectusbio.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://provectusbio.com/role/SignificantAccountingPolicies 13 false false R14.htm 00000014 - Disclosure - Liquidity and Going Concern (Details Narrative) Sheet http://provectusbio.com/role/LiquidityAndGoingConcernDetailsNarrative Liquidity and Going Concern (Details Narrative) Details http://provectusbio.com/role/LiquidityAndGoingConcern 14 false false R15.htm 00000015 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://provectusbio.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://provectusbio.com/role/ConvertibleNotesPayable 15 false false R16.htm 00000016 - Disclosure - Stockholders' Deficiency (Details Narrative) Sheet http://provectusbio.com/role/StockholdersDeficiencyDetailsNarrative Stockholders' Deficiency (Details Narrative) Details http://provectusbio.com/role/StockholdersDeficiency 16 false false R17.htm 00000017 - Disclosure - Litigation (Details Narrative) Sheet http://provectusbio.com/role/LitigationDetailsNarrative Litigation (Details Narrative) Details http://provectusbio.com/role/Litigation 17 false false R18.htm 00000018 - Disclosure - Subsequent Events (Details Narrative) Sheet http://provectusbio.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://provectusbio.com/role/SubsequentEvents 18 false false All Reports Book All Reports pvct-20180630.xml pvct-20180630.xsd pvct-20180630_cal.xml pvct-20180630_def.xml pvct-20180630_lab.xml pvct-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 35 0001493152-18-011091-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-011091-xbrl.zip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